Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Approval of Concerta for ADHD Withheld
October 15, 2007
- Inhibition of Both Absorption and Production of LDL-C Important: Schering-Plough
October 15, 2007
- Argatroban Applied for HIT Based on Results of Physician-Initiated Trial
October 15, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 15, 2007
- REGULATORY NEWS IN BRIEF
October 15, 2007
- SELF-MEDICATION NEWS IN BRIEF
October 15, 2007
- COMMENTARY／FPMAJ's Drug Pricing System Reform Proposal Meets with Objection
October 15, 2007
- NEW PRODUCTS
October 15, 2007
- Problems with Generics Pointed Out in 19/40 Studies
October 15, 2007
- Merck Serono Sets Out Focusing on Cancer, Infertility
October 15, 2007
- 3 Domestic Generic Firms to Hold IR Meeting in London
October 15, 2007
- Mylan Enters Market in Japan by Acquiring Merck's Generic Drug Business
October 15, 2007
- Public Opinions Invited on Documents Required for Applications for Generics
October 15, 2007
- Mitsubishi Tanabe Pharma Corp. Aims at Becoming Global Drug Discovery Company
October 15, 2007
- Kaken Completes PIIb Trial for KCB-1D as Drug to Regenerate Periodontal Tissue
October 15, 2007
- Taisho Licenses Psychiatric Drug Candidates to BrainCells
October 15, 2007
- Silodosin Was Found to Be Superior to Tamsulosin: Kissei
October 15, 2007
- EPS Ties Up with Medidata Solutions Regarding EDC Software
October 15, 2007
- First Gene Therapeutic to Regenerate Blood Vessels Expected in 2008
October 15, 2007
- VITAL-NET, KSK Enter into Comprehensive Business Alliance
October 15, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…